Navigation Links
AcelRx Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/8/2013

REDWOOD CITY, Calif., May 8, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the first quarter ended March 31, 2013.

"We continue to make progress in clinical development of our product candidates.  We presented additional data at the recent American Society of Regional Anesthesia and Pain Medicine meeting from a head-to-head study of the Sufentanil NanoTab PCA System compared to intravenous morphine that showed rapid post-operative pain reduction and low rates of oxygen desaturation for the NanoTab system treated patients," stated Richard King , president and CEO of AcelRx.  "This highly encouraging data reinforces our selection of sufentanil, a fast-acting opioid with a high therapeutic index, to combine with our pre-programmed, non-invasive patient-controlled delivery technology. We also completed enrollment and look forward to announcing top-line results later this quarter from our third and final Phase 3 trial conducted with the NanoTab System in patients who have undergone hip or knee replacement surgery."  Mr. King added, "We were also very pleased to announce positive Phase 2 top-line results for ARX-04, a single-dose, sufentanil NanoTab product candidate administered by healthcare professionals for the management of moderate-to-severe acute pain, in which we successfully identified that a 30 mcg dose of sufentanil delivered no more frequently than hourly is an effective dose."

First Quarter Financial ResultsNet loss for the first quarter of 2013 was $12.8 million, or $0.34 per share, compared with a net loss of $7.1 million, or $0.36 per share for the first quarter
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
2. AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
3. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
4. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
5. AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013
6. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
7. AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. AcelRx Pharmaceuticals Provides Clinical Trial Updates
9. AcelRx Appoints Adrian Adams to Board of Directors as Chairman
10. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
11. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... and RALEIGH, N.C. , ... Communications, LLC (CTMC), and Integrated Clinical Trial Services, ... and retention for clinical trials announce that they ... Trial Marketing Services (i-CTMS). i-CTMS will provide a ... to pharmaceutical, biotechnology and medical device companies. ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... "Inferior Vena Cava (IVC) Filters - Global Trends, ... http://photos.prnewswire.com/prnh/20130307/600769 ... to reach US$435 million by 2016. The ... of the global value while Europe ...
(Date:12/15/2014)... N.J. , Dec. 15, 2014   Regeneron ... and NYSE: SNY) are collaborating with nationally-recognized patient and ... , an awareness program that will gauge how much ... associated with high LDL-C (bad cholesterol).  American adults are ... take a brief poll and answer a few key ...
Breaking Medicine Technology:Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6
... March 6, 2012 Biospace Lab S.A. ... College London will collaborate on the development of novel ... of the Biospace Lab PhotonIMAGER™ Optima pre-clinical imaging platform. ... Dr Mark Lythgoe, and molecular probes, Dr Martin Pule, ...
... GP Strategies Corporation (NYSE: GPX ), ... sales and technical training, e-Learning solutions, management consulting and ... CFO Sharon Esposito-Mayer will speak at the ROTH Capital ... 3:30 p.m. PT. The conference will be held at ...
Cached Medicine Technology:Biospace Lab and the Centre for Advanced Biomedical Imaging at University College London to Collaborate on Development of Novel Real-Time in Vivo Optical Imaging Technologies 2
(Date:12/17/2014)... TUESDAY, Dec. 16, 2014 (HealthDay News) -- Greater participation ... new study finds. Researchers followed kids in the ... to poor children in Los Angeles. Over two ... larger improvements in how the brain processes speech and ... Also, the benefits of active participation in music ...
(Date:12/15/2014)... A recent survey found that the ... impacting skin health and beauty were: “Connections,” “climate,” “career” ... Water and health advocate and radio host Sharon Kleyne ... the survey and the Four C’s.* Kleyne notes, however, ... discussed would benefit from paying attention to one’s daily ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... Steven Reinberg HealthDay Reporter ... large, new study should reassure the millions of American women ... for breast cancer. "There is no association between migraine ... associate professor of medicine at Harvard Medical School. "There is ... and there is no protective effect either." About 18 ...
(Date:12/15/2014)... Austin, TX (PRWEB) December 15, 2014 ... with offices in 26 countries in North and South ... begun accepting responses from industry participants for its 2015 ... survey in order to identify upcoming business and market ... industry respondents. , The survey targets areas including:, ...
Breaking Medicine News(10 mins):Health News:Music Classes Boost Language Skills, Study Says 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2
... and public campaigner, has made known the fact that she ... , Dame Anita known worldwide for her company, ... was infected with the virus in 1971 via infected blood, ... businesswoman who is well known for her indefatigable campaigning has ...
... Organization (PAHO) are working with health authorities in Paraguay ... has affected a// number of communities throughout the nation ... America. ,PAHO officials warn that the entire ... prepare for what promises to be a "difficult year" ...
... A recent study by scientists at University of Wisconsin-Madison ... hear better. ,Led by Ruth Litovsky, an ... suggests that deaf children who have a cochlear implant ... use both implants instead of one. Children with two ...
... treatment for an abdominal aortic aneurysm, a weak spot ... time. If the vessel ruptures suddenly before surgery to ... scientists say they have identified a key enzyme that ... growth of aneurysms. Their finding raises hopes for developing ...
... omega-3 fatty acids on their own can alleviate depression, ... there is only limited evidence that they can relieve ... adds. ,Evidence from circumstantial research has suggested ... such as depression. And the findings have attracted widespread ...
... bottle-fed children, reveals a large, long term study, published// ahead ... ,Over 3000 children from 16 rural and urban areas ... of the Boyd Orr Study of Diet and Health in ... on 1414 people in their 60s and 70s, for whom ...
Cached Medicine News:Health News:Body Shop Founder’s New Project-against Hepatitis 2Health News:PAHO Urges Readiness for Dengue Outbreaks in 2007 2Health News:Cochlear Implants in Both Ears Enables Better Hearing 2Health News:Cochlear Implants in Both Ears Enables Better Hearing 3Health News:Enzyme Critical for Early Growth of Abdominal Aortic Aneurysms 2Health News:Enzyme Critical for Early Growth of Abdominal Aortic Aneurysms 3
...
...
Rhoton Curettes, titanium, length 191 mm, straight....
Sundt Slim-Line Temporary Vessel Clips used for temporary vascular occlusion during intracranial surgical procedures. Non-magnetic, MP35N, MRI compatible, gold color. Bayonet....
Medicine Products: